121 related articles for article (PubMed ID: 37934043)
41. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of Galectin3 levels in psoriatic patients treated by narrow-band UVB phototherapy.
Khater MH; AbdallaAlhabib S; Elkshishy KA; Khattab FM
J Dermatolog Treat; 2020 Dec; 31(8):758-762. PubMed ID: 31557066
[No Abstract] [Full Text] [Related]
43. Elevation of serum squamous cell carcinoma antigen 2 in patients with psoriasis: associations with disease severity and response to the treatment.
Watanabe Y; Yamaguchi Y; Komitsu N; Ohta S; Azuma Y; Izuhara K; Aihara M
Br J Dermatol; 2016 Jun; 174(6):1327-36. PubMed ID: 26822223
[TBL] [Abstract][Full Text] [Related]
44. Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis.
Baran A; Kiluk P; Maciaszek M; Świderska M; Flisiak I
Arch Dermatol Res; 2019 Jul; 311(5):389-397. PubMed ID: 30993401
[TBL] [Abstract][Full Text] [Related]
45. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
Zagni E; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Zullo A; Fiocchi M; Colombo D
BMC Health Serv Res; 2021 Sep; 21(1):924. PubMed ID: 34488749
[TBL] [Abstract][Full Text] [Related]
46. Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
Engin B; Tanakol A; Bulut H; Songür A; Vehid HE; Gökalp E; Kutlubay Z; Özkoca D; Tüzün Y; Serdaroğlu S
Int J Dermatol; 2020 Feb; 59(2):207-215. PubMed ID: 31531981
[TBL] [Abstract][Full Text] [Related]
47. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J
Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093
[TBL] [Abstract][Full Text] [Related]
48. Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting.
Gulliver WP; Randell S; Gulliver S; Gregory V; Nagle S; Chambenoit O
J Cutan Med Surg; 2018; 22(6):567-576. PubMed ID: 29952225
[TBL] [Abstract][Full Text] [Related]
49. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
50. Serum YKL-40 and IL 17 in Psoriasis: Reliability as prognostic markers for disease severity and responsiveness to treatment.
Khashaba SA; Attwa E; Said N; Ahmed S; Khattab F
Dermatol Ther; 2021 Jan; 34(1):e14606. PubMed ID: 33249724
[TBL] [Abstract][Full Text] [Related]
51. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
52. Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain.
Daudén E; Vidal D; Romero A; Bordel MT; Rivera R; Márquez J; Zamora E; Martinez L; Ocaña MJ; Vila C; Iribarren P; Corona N; Zulaica A
Actas Dermosifiliogr; 2024 Jan; 115(1):T1-T9. PubMed ID: 37923068
[TBL] [Abstract][Full Text] [Related]
53. Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain.
Daudén E; Vidal D; Romero A; Bordel MT; Rivera R; Márquez J; Zamora E; Martinez L; Ocaña MJ; Vila C; Iribarren P; Corona N; Zulaica A
Actas Dermosifiliogr; 2024 Jan; 115(1):1-9. PubMed ID: 37429433
[TBL] [Abstract][Full Text] [Related]
54. Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis.
Kozłowska D; Myśliwiec H; Harasim-Symbor E; Milewska AJ; Chabowski A; Flisiak I
Mol Biol Rep; 2021 May; 48(5):4421-4429. PubMed ID: 34131888
[TBL] [Abstract][Full Text] [Related]
55. Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry.
Bonomo L; Abittan BJ; Hashim PW; Karki C; Mason M; Lebwohl M
J Drugs Dermatol; 2019 Aug; 18(8):731-740. PubMed ID: 31424705
[TBL] [Abstract][Full Text] [Related]
56. Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index.
Elnabawi YA; Oikonomou EK; Dey AK; Mancio J; Rodante JA; Aksentijevich M; Choi H; Keel A; Erb-Alvarez J; Teague HL; Joshi AA; Playford MP; Lockshin B; Choi AD; Gelfand JM; Chen MY; Bluemke DA; Shirodaria C; Antoniades C; Mehta NN
JAMA Cardiol; 2019 Sep; 4(9):885-891. PubMed ID: 31365032
[TBL] [Abstract][Full Text] [Related]
57. The Effect of Three-Month Vitamin D Supplementation on the Levels of Homocysteine Metabolism Markers and Inflammatory Cytokines in Sera of Psoriatic Patients.
Prtina A; Rašeta Simović N; Milivojac T; Vujnić M; Grabež M; Djuric D; Stojiljković MP; Soldat Stanković V; Čolić MJ; Škrbić R
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944509
[TBL] [Abstract][Full Text] [Related]
58. Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography.
Dey AK; Joshi AA; Chaturvedi A; Lerman JB; Aberra TM; Rodante JA; Teague HL; Harrington CL; Rivers JP; Chung JH; Kabbany MT; Natarajan B; Silverman JI; Ng Q; Sanda GE; Sorokin AV; Baumer Y; Gerson E; Prussick RB; Ehrlich A; Green LJ; Lockshin BN; Ahlman MA; Playford MP; Gelfand JM; Mehta NN
JAMA Cardiol; 2017 Sep; 2(9):1013-1018. PubMed ID: 28564678
[TBL] [Abstract][Full Text] [Related]
59. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
[TBL] [Abstract][Full Text] [Related]
60. High levels of serum vitamin D-binding protein in patients with psoriasis: A case-control study and effects of ultraviolet B phototherapy.
Vandikas MS; Landin-Wilhelmsen K; Holmäng A; Gillstedt M; Osmancevic A
J Steroid Biochem Mol Biol; 2021 Jul; 211():105895. PubMed ID: 33819632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
